What’s happening at Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE)? What made the stock one of the top performing stock today? The company is indeed among the top gainers of the stock market, skyrocketing 4.55% (or 1.99 points) to $45.72 from its previous close of $43.73. So is it the right moment to buy?
The shares had an increased trading volume of 799,327 contracts this session compared to the average daily volume of last 10 days of 461,900 contracts and they had an increased trading volume compared to the average daily volume of last 3 months of 546,812 contracts.
The indicator of a company’s profitability, the earnings per share ratio is -7.24. This value shows how much money a company makes for each share of its stock. A higher EPS indicates more value because investors will pay more for a company with higher profits. This is negative and tells you exactly how much money the company lost per share of its 57.8M outstanding stock.
The closing market price for this trading session was 29.12% over 52 weeks minimum price of $35.41 and 38.63% under 52 weeks maximum price of $74.50. Also the price is -8.11% less than 200 day average of $49.76 and 14.37% greater than 50 day average of $39.98.
Latest news that might have contributed to the great perfomance of RARE today are:
- Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma, published on Wed, 18 Dec 2019 13:30:10 +0000
- Do Hedge Funds Love Ultragenyx Pharmaceutical Inc (RARE)?, published on Wed, 11 Dec 2019 02:11:25 +0000
- Astellas-Audentes Deal Likely to Ignite More Acquisitions, published on Thu, 05 Dec 2019 21:32:34 +0000